Iovance Biotherapeutics (NasdaqGM:IOVA) recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its ...

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research ...

Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a report issued ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current ...

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price ...

Iovance Biotherapeutics Inc (IOVA) reaches revenue targets and plans global expansion, despite facing competition and ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 19.49%, which has investors questioning if this is right time ...

Although it reported 2024 Q4 and full-year results that beat expectations and reiterated 2025 guidance that includes ...

The commercial-stage biotechnology company posted revenue of $73.7 million for the quarter, missing the consensus estimate of $77.33 million. However, adjusted earnings per share came in at -$0.26, ...